Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5342803 | 0.85 | PDE5A (0.49) | PDE5ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| Dimethylamine SCHEMBL5344867 | 0.83 | PDE5A (0.47) | PDE5ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3929270 | 0.82 | PDE5A (0.47) | PDE5ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL124547 | 0.77 | CYP1A2 (0.44) | PDE5ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21211527 | 0.76 | ADORA1 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4NPC1 | |
| SCHEMBL5345637 | 0.76 | CDK5 (0.53) | PDE5AGBA1 | |
| SCHEMBL3926995 | 0.74 | GRM5 (0.44) | GBA1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL3926330 | 0.74 | ITGB1 (0.47) | PDE5ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5338014 | 0.73 | NOS1 (0.59) | ALOX5NOS1 | |
| SCHEMBL3928490 | 0.72 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1309589-B1 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | PDE5A 1638/4885CHRNB2 4867/4885CHRNB4 4866/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | PDE5A 872/4885CHRNB2 4825/4885CHRNB4 4845/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | PDE5A 1638/4885CHRNB2 4867/4885CHRNB4 4866/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | PDE5A 1638/4885CHRNB2 4867/4885CHRNB4 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.